LLY
NKTR
Courtroom plot twist
Eli Lilly just took a legal punch to the gut. A federal jury in California found that the company breached the implied covenant of good faith and fair dealing in its licensing deal with Nektar Therapeutics and awarded Nektar $90 million in damages.
Why this matters
This wasn’t some dusty contract squabble over coffee stains and fine print. The case stems from a licensing agreement tied to rezpegaldesleukin, a drug program both companies have had skin in the game on. For Nektar, the verdict is a loud validation — plus a potential cash boost if the award survives the legal cleanup.
For Lilly, the hit is more awkward than existential, but still not great. The $90 million award can grow once interest is added, and the verdict is still subject to post-trial proceedings. Translation: this isn’t necessarily the final scene in the movie.
The investor takeaway
You’re looking at a two-sided stock story:
- NKTR gets a meaningful legal win and a cleaner narrative around one of its asset stories.
- LLY gets a reminder that even mega-cap pharma can end up paying for old deal drama.
Big picture: courtroom wins can matter, but they’re especially spicy when they land on top of an active drug pipeline story. Nektar just got a fresh tailwind; Lilly got a tiny bruise on a very big balance sheet.